Digital Health
-
Cutting-Edge Client Base
At Wilson Sonsini, we focus on representing emerging and high-growth digital health companies that are transforming healthcare through technology, data, and AI-powered solutions.
-
Comprehensive Health Tech Expertise
Our expertise covers a broad spectrum of health tech, from telehealth and wellness apps to medical devices and AI-driven drug discovery.
-
Leading Advisor to Digital Health Innovators
Wilson Sonsini has more than 600 digital health clients, including 28 unicorns.
-
More than $30 Billion in Venture Financings
Since 2000, we’ve assisted U.S.-based digital health clients in raising more than $30 billion in aggregate seed and venture funding.
Wilson Sonsini represents digital health companies and their venture investors in nearly all areas of health tech, including telehealth and telemedicine, mobile health and wellness apps and platforms, healthcare data analytics, wearables, medical devices, wellness products, digital therapeutics, data/AI drug discovery, and precision medicine.
Our multidisciplinary team provides comprehensive support in all areas critical to digital health companies’ growth and success, including:
- Company formation
- Healthcare regulatory advising and corporate practice of medicine structuring
- FDA pre- and post-approval counseling
- Venture capital financings
- Commercial transactions
- AI development and utilization
- Patents, trademarks, and intellectual property protections
- HIPAA compliance and healthcare data privacy
- Litigation and enforcement
- Mergers & acquisitions
- Initial public offerings (IPOs)
With a focus on emerging companies, Wilson Sonsini has robust experience navigating legal risks associated with the use of the most cutting-edge technology in healthcare. These technologies often outpace the legislatures and courts tasked with regulating them, requiring advice that balances legal, ethical, and business needs. Our team offers creative solutions to compliance obstacles tailored to the company’s stage, size, and risk tolerance, with rapid turnaround times and cost-effective advising, including fixed-fee pricing options.
Overview
Wilson Sonsini represents digital health companies and their venture investors in nearly all areas of health tech, including telehealth and telemedicine, mobile health and wellness apps and platforms, healthcare data analytics, wearables, medical devices, wellness products, digital therapeutics, data/AI drug discovery, and precision medicine.
Our multidisciplinary team provides comprehensive support in all areas critical to digital health companies’ growth and success, including:
- Company formation
- Healthcare regulatory advising and corporate practice of medicine structuring
- FDA pre- and post-approval counseling
- Venture capital financings
- Commercial transactions
- AI development and utilization
- Patents, trademarks, and intellectual property protections
- HIPAA compliance and healthcare data privacy
- Litigation and enforcement
- Mergers & acquisitions
- Initial public offerings (IPOs)
With a focus on emerging companies, Wilson Sonsini has robust experience navigating legal risks associated with the use of the most cutting-edge technology in healthcare. These technologies often outpace the legislatures and courts tasked with regulating them, requiring advice that balances legal, ethical, and business needs. Our team offers creative solutions to compliance obstacles tailored to the company’s stage, size, and risk tolerance, with rapid turnaround times and cost-effective advising, including fixed-fee pricing options.
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
Wilson Sonsini Advises Luminopia on Licensing Agreement with ROHTO
On June 2, 2026, Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Luminopia on the transaction.
Client Highlights
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
Wilson Sonsini Advises Ultralight on $9.3 Million Seed Funding
On April 13, 2026, Ultralight, the AI-native operating system for modern medicine, announced that it has raised $9.3 million in seed funding. The round was led by The General Partnership, with participation from Wisdom Ventures, Anthemis Group, Emerson Collective, GSBackers, and various angel investors. Wilson Sonsini Goodrich & Rosati advised Ultralight on the transaction.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Insights
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
Wilson Sonsini Advises Luminopia on Licensing Agreement with ROHTO
On June 2, 2026, Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Luminopia on the transaction.
Client Highlights
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
Wilson Sonsini Advises Ultralight on $9.3 Million Seed Funding
On April 13, 2026, Ultralight, the AI-native operating system for modern medicine, announced that it has raised $9.3 million in seed funding. The round was led by The General Partnership, with participation from Wisdom Ventures, Anthemis Group, Emerson Collective, GSBackers, and various angel investors. Wilson Sonsini Goodrich & Rosati advised Ultralight on the transaction.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Affiliated Programs
The L Suite 2026 TechGC New York Digital Health Forum
Wilson Sonsini will sponsor The L Suite 2026 TechGC New York Digital Health Forum, a half-day event designed for general counsel and chief legal officers in the industry. Multiple content sessions will explore emerging legal challenges, including oversight of AI-enabled products, compliance obligations for data sharing, and expanding liability tied to model transparency and data provenance. Participants will discuss how evolving FDA, CMS, and DEA priorities are shaping both legal and business strategy.
WSGR Events
2026 Medical Device & Digital Health Conference
Wilson Sonsini’s 33rd Annual Medical Device & Digital Health Conference convenes industry leaders, investors, and innovators to explore the forces shaping medical device technology and digital health today. The program delivers valuable insights across innovation, regulation, capital markets, and commercialization, addressing topics of critical importance to companies navigating strategic growth and transformation.
Affiliated Programs
The L Suite 2026 TechGC Bay Area Digital Health Forum
In partnership with The L Suite, Wilson Sonsini will co-host 2026 TechGC Bay Area Digital Health Forum, a half-day for general counsel and senior legal leaders from health technology companies. The Forum emphasizes real-world perspective, collaborative problem-solving, and actionable takeaways for legal leaders navigating constant change across the digital health landscape.
Affiliated Programs
Next-Level Health Systems Summit: Leading with AI
Wilson Sonsini is pleased to sponsor the Next-Level Health Systems Summit: Leading with AI. No doubt that AI is reshaping the healthcare landscape and it is already embedded in clinical workflows, infrastructure stacks, and executive decision-making. The question is no longer whether to adopt AI, but where it truly delivers value, where it creates friction, and how to navigate both the transformative potential and the operational realities it entails.
Speaking Engagements
AHLA Health Care Transactions Conference
On April 15th Wilson Sonsini partner Andrea Linna will present on the panel “Representing the Founders, Investors, and Innovators of Healthcare AI: Venture Capital and Emerging Companies.” The session will explore the central role venture capital plays in bringing healthcare AI to market and the complex legal landscape that founders and investors must navigate.
Events
Affiliated Programs
The L Suite 2026 TechGC New York Digital Health Forum
Wilson Sonsini will sponsor The L Suite 2026 TechGC New York Digital Health Forum, a half-day event designed for general counsel and chief legal officers in the industry. Multiple content sessions will explore emerging legal challenges, including oversight of AI-enabled products, compliance obligations for data sharing, and expanding liability tied to model transparency and data provenance. Participants will discuss how evolving FDA, CMS, and DEA priorities are shaping both legal and business strategy.
WSGR Events
2026 Medical Device & Digital Health Conference
Wilson Sonsini’s 33rd Annual Medical Device & Digital Health Conference convenes industry leaders, investors, and innovators to explore the forces shaping medical device technology and digital health today. The program delivers valuable insights across innovation, regulation, capital markets, and commercialization, addressing topics of critical importance to companies navigating strategic growth and transformation.
Affiliated Programs
The L Suite 2026 TechGC Bay Area Digital Health Forum
In partnership with The L Suite, Wilson Sonsini will co-host 2026 TechGC Bay Area Digital Health Forum, a half-day for general counsel and senior legal leaders from health technology companies. The Forum emphasizes real-world perspective, collaborative problem-solving, and actionable takeaways for legal leaders navigating constant change across the digital health landscape.
Affiliated Programs
Next-Level Health Systems Summit: Leading with AI
Wilson Sonsini is pleased to sponsor the Next-Level Health Systems Summit: Leading with AI. No doubt that AI is reshaping the healthcare landscape and it is already embedded in clinical workflows, infrastructure stacks, and executive decision-making. The question is no longer whether to adopt AI, but where it truly delivers value, where it creates friction, and how to navigate both the transformative potential and the operational realities it entails.
Speaking Engagements
AHLA Health Care Transactions Conference
On April 15th Wilson Sonsini partner Andrea Linna will present on the panel “Representing the Founders, Investors, and Innovators of Healthcare AI: Venture Capital and Emerging Companies.” The session will explore the central role venture capital plays in bringing healthcare AI to market and the complex legal landscape that founders and investors must navigate.
Jodi Daniel
Partner
Jodi Daniel is a nationally recognized leader in digital health law and policy, trusted by health care organizations and technology innovators to navigate the complex and dynamic regulatory landscape of digital health and wellness. With over 30 years of experience in healthcare innovation—including 15 years as a lawyer and senior policymaker at the U.S. Department of Health and Human Services (HHS)—Jodi leverages her extensive experience in digital health and health data to deliver strategic, practical advice to clients engaged in groundbreaking products and services that raise novel legal, policy, and ethical issues.
Andrea Linna
Partner
Andrea Linna is a partner at Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s digital health industry group and its healthcare practice. With more than a decade dedicated to healthcare law, Andrea exclusively represents digital health and healthcare IT clients, from emerging companies to established industry players, investors, and healthcare systems. Andrea guides her clients through the patchwork of federal and state laws that apply to digital health companies, addressing issues such as corporate practice of medicine, Stark Law compliance, Anti-Kickback Statute considerations, fee splitting, billing Medicare and Medicaid, contracting with commercial payors, value-based care arrangements, artificial intelligence, remote patient monitoring, online prescribing, scope of practice, and licensing requirements.
Eva F. Yin
Partner
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
Rob Parr
Partner
Rob Parr is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati, where he leads the office’s information technology transactions practice. He represents companies in transactions focused on the exploitation of intellectual property rights and technology in a variety of industries. Rob represents many companies in the digital health industry in particular and plays a key role in the firm’s digital health initiative. He regularly drafts and negotiates a wide variety of complex commercial agreements, including services, distribution, strategic alliance and joint venture, supply, asset transfer, and intellectual property license agreements. Rob also represents clients with the intellectual property and commercial issues arising from financings, mergers, acquisitions, and initial public offerings.
Lang Liu
Partner
Lang represents public and private companies, investment banks and venture capital firms.
Megan J. Baier
Partner
Megan represents technology and life sciences clients in corporate transactional matters.
Mark B. Baudler
Partner
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
Farah B. Gerdes
Partner
Farah focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions.
Ali R. Alemozafar
Partner
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
People
Jodi Daniel
Partner
Jodi Daniel is a nationally recognized leader in digital health law and policy, trusted by health care organizations and technology innovators to navigate the complex and dynamic regulatory landscape of digital health and wellness. With over 30 years of experience in healthcare innovation—including 15 years as a lawyer and senior policymaker at the U.S. Department of Health and Human Services (HHS)—Jodi leverages her extensive experience in digital health and health data to deliver strategic, practical advice to clients engaged in groundbreaking products and services that raise novel legal, policy, and ethical issues.
Andrea Linna
Partner
Andrea Linna is a partner at Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s digital health industry group and its healthcare practice. With more than a decade dedicated to healthcare law, Andrea exclusively represents digital health and healthcare IT clients, from emerging companies to established industry players, investors, and healthcare systems. Andrea guides her clients through the patchwork of federal and state laws that apply to digital health companies, addressing issues such as corporate practice of medicine, Stark Law compliance, Anti-Kickback Statute considerations, fee splitting, billing Medicare and Medicaid, contracting with commercial payors, value-based care arrangements, artificial intelligence, remote patient monitoring, online prescribing, scope of practice, and licensing requirements.
Eva F. Yin
Partner
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
Rob Parr
Partner
Rob Parr is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati, where he leads the office’s information technology transactions practice. He represents companies in transactions focused on the exploitation of intellectual property rights and technology in a variety of industries. Rob represents many companies in the digital health industry in particular and plays a key role in the firm’s digital health initiative. He regularly drafts and negotiates a wide variety of complex commercial agreements, including services, distribution, strategic alliance and joint venture, supply, asset transfer, and intellectual property license agreements. Rob also represents clients with the intellectual property and commercial issues arising from financings, mergers, acquisitions, and initial public offerings.
Lang Liu
Partner
Lang represents public and private companies, investment banks and venture capital firms.
Megan J. Baier
Partner
Megan represents technology and life sciences clients in corporate transactional matters.
Mark B. Baudler
Partner
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
Farah B. Gerdes
Partner
Farah focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions.
Ali R. Alemozafar
Partner
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
WSGR On-Demand Learning
- Digital Health Webinar Series - Session 1: Navigating the Legal Complexities of Digital Healthcare Regulations
- Digital Health Webinar Series - Session 2: Corporate Practice of Medicine
- Digital Health Webinar Series - Session 3: Value Based Care
- Digital Health Webinar Series - Session 4: Interoperability and Information Blocking Regulations
- Digital Health Webinar Series - Session 5: Marketing and Advertising for Digital Health Companies
- Digital Health Webinar Series - Session 6: AI in the Digital Health Industry: Key Regulatory, IP, and Commercial Topics
- Digital Health Webinar Series - Session 7: Privacy & Artificial Intelligence
Credit for online viewing with checkpoints is available in California (participatory), New York (experienced attorneys only), and Texas (accredited). For questions regarding any other states, please contact Wilson Sonsini’s MCLE Manager. Please note that you may be prompted to create an account the first time you access the site.
Webinars
WSGR On-Demand Learning
- Digital Health Webinar Series - Session 1: Navigating the Legal Complexities of Digital Healthcare Regulations
- Digital Health Webinar Series - Session 2: Corporate Practice of Medicine
- Digital Health Webinar Series - Session 3: Value Based Care
- Digital Health Webinar Series - Session 4: Interoperability and Information Blocking Regulations
- Digital Health Webinar Series - Session 5: Marketing and Advertising for Digital Health Companies
- Digital Health Webinar Series - Session 6: AI in the Digital Health Industry: Key Regulatory, IP, and Commercial Topics
- Digital Health Webinar Series - Session 7: Privacy & Artificial Intelligence
Credit for online viewing with checkpoints is available in California (participatory), New York (experienced attorneys only), and Texas (accredited). For questions regarding any other states, please contact Wilson Sonsini’s MCLE Manager. Please note that you may be prompted to create an account the first time you access the site.
Related Practices
- Capital Markets
- Corporate
- Corporate Governance
- Corporate Life Sciences
- Data, Privacy, and Cybersecurity
- FDA Regulatory, Healthcare, and Consumer Products
- Federal Trade Commission
- Government Investigations
- Internet Strategy and Litigation
- Life Sciences Business Advisory Practice
- Mergers & Acquisitions
- Patents and Innovations
- Public Company Representation
- Regulatory
- Technology Transactions
- Trademark and Advertising
- U.S. Expansion
Recent Insights
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Learn More
Client Highlights
Wilson Sonsini Advises Luminopia on Licensing Agreement with ROHTO
On June 2, 2026, Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Luminopia on the transaction.
Learn More
Recent Events
Affiliated Programs
The L Suite 2026 TechGC New York Digital Health Forum
Wilson Sonsini will sponsor The L Suite 2026 TechGC New York Digital Health Forum, a half-day event designed for general counsel and chief legal officers in the industry. Multiple content sessions will explore emerging legal challenges, including oversight of AI-enabled products, compliance obligations for data sharing, and expanding liability tied to model transparency and data provenance. Participants will discuss how evolving FDA, CMS, and DEA priorities are shaping both legal and business strategy.
Learn More
WSGR Events
2026 Medical Device & Digital Health Conference
Wilson Sonsini’s 33rd Annual Medical Device & Digital Health Conference convenes industry leaders, investors, and innovators to explore the forces shaping medical device technology and digital health today. The program delivers valuable insights across innovation, regulation, capital markets, and commercialization, addressing topics of critical importance to companies navigating strategic growth and transformation.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.